Author:
Chaudhry Dhruva,Aggarwal Richa,Kumar Prashant,Singh Pawan K,Lalwani Lokesh K,Govindagoudar Manjunath B,Gehlaut Preeti
Publisher
Jaypee Brothers Medical Publishing
Subject
Critical Care and Intensive Care Medicine
Reference16 articles.
1. 1. Soin AS, Kumar K, Choudhary NS, Sharma P, Mehta Y, Kataria S, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 2021;9(5):511–521. DOI: 10.1016/S2213-2600(21)00081-3.
2. 2. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. New Engl J Med 2020;384(9):795–807. DOI: 10.1056/NEJMoa2031994.
3. 3. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016;34(2):318–328. www.clinexprheumatol.org/abstract.asp?a=9615
4. 4. Hayek ME, Mansour M, Ndetan H, Burkes Q, Corkren R, Dulli A, et al. Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort. Mayo Clin Proc Innov Qual Outcomes 2021;5(3):605–613. DOI: 10.1016/j.mayocpiqo.2021.03.007.
5. 5. Panés J, Gisbert JP. Efficacy of tofacitinib treatment in ulcerative colitis. Gastroenterol Hepatol 2019;42(6):403–412. DOI: 10.1016/j.gastrohep.2019.03.002.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献